Indeed, we see that combining SMOi treatment with AP-1 inhibition or ALK5 inhibition in resistant BCC cells leads to increased levels of cell death than with SMOi alone (Fig. 3j). The gene discussed is FOS; the disease is skin basal cell carcinoma.